|
1
|
Johnson CA, James D, Marzan A and Armaos
M: Cervical Cancer: An Overview of Pathophysiology and Management.
Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liontos M, Kyriazoglou A, Dimitriadis I,
Dimopoulos MA and Bamias A: Systemic therapy in cervical cancer: 30
years in review. Crit Rev Oncol Hematol. 137:9–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leahy AB, Elgarten CW, Grupp SA, Maude SL
and Teachey DT: Tisagenlecleucel for the treatment of B-cell acute
lymphoblastic leukemia. Expert Rev Anticancer Ther. 18:959–971.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kwok G, Yau TC, Chiu JW, Tse E and Kwong
YL: Pembrolizumab (Keytruda). Hum Vaccin Immunother. 12:2777–2789.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang J, Zhang H and Jin S: Epigenetics and
cervical cancer: From pathogenesis to therapy. Tumour Biol.
35:5083–5093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krieg P, Marks F and Fürstenberger G: A
gene cluster encoding human epidermis-type lipoxygenases at
chromosome 17p13.1: Cloning, physical mapping, and expression.
Genomics. 73:323–330. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mashima R and Okuyama T: The role of
lipoxygenases in pathophysiology; new insights and future
perspectives. Redox Biol. 6:297–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurban M, Shimomura Y, Bahhady R, Ghosn S,
Kibbi AG and Christiano AM: Nonsense mutation in the ALOX12B gene
leads to autosomal recessive congenital ichthyosis in a Lebanese
family. J Eur Acad Dermatol Venereol. 24:232–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rodríguez-Pazos L, Ginarte M, Vega A and
Toribio J: Autosomal recessive congenital ichthyosis. Actas
Dermosifiliogr. 104:270–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen M, Vermeulen R, Rajaraman P, Menashe
I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A,
et al: Polymorphisms in innate immunity genes and lung cancer risk
in Xuanwei, China. Environ Mol Mutagen. 50:285–290. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JY, Park AK, Lee KM, Park SK, Han S,
Han W, Noh DY, Yoo KY, Kim H, Chanock SJ, et al: Candidate gene
approach evaluates association between innate immunity genes and
breast cancer risk in Korean women. Carcinogenesis. 30:1528–1531.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Agarwal S, Achari C, Praveen D, Roy KR,
Reddy GV and Reddanna P: Inhibition of 12-LOX and COX-2 reduces the
proliferation of human epidermoid carcinoma cells (A431) by
modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol.
18:939–946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bernard B, Fest T, Prétet JL and Mougin C:
Staurosporine-induced apoptosis of HPV positive and negative human
cervical cancer cells from different points in the cell cycle. Cell
Death Differ. 8:234–244. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khajah MA, Mathew PM and Luqmani YA:
Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity
Against Endocrine-Resistant Breast Cancer Cells. Oncol Res.
25:1283–1295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taciak B, Pruszynska I, Kiraga L, Bialasek
M and Krol M: Wnt signaling pathway in development and cancer. J
Physiol Pharmacol. 69:692018.
|
|
21
|
Zeng H: mTOR signaling in immune cells and
its implications for cancer immunotherapy. Cancer Lett.
408:182–189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsikouras P, Zervoudis S, Manav B, Tomara
E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical
cancer: Screening, diagnosis and staging. J BUON. 21:320–325.
2016.PubMed/NCBI
|
|
23
|
Le Gallo M, Lozy F and Bell DW:
Next-Generation Sequencing. Adv Exp Med Biol. 943:119–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang S, Sun L and Feng G: SP1-mediated
long noncoding RNA POU3F3 accelerates the cervical cancer through
miR-127-5p/FOXD1. Biomed Pharmacother. 117:1091332019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fasterius E, Uhlén M and Al-Khalili
Szigyarto C: Single-cell RNA-seq variant analysis for exploration
of genetic heterogeneity in cancer. Sci Rep. 9:95242019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crook T, Wrede D, Tidy JA, Mason WP, Evans
DJ and Vousden KH: Clonal p53 mutation in primary cervical cancer:
Association with human-papillomavirus-negative tumours. Lancet.
339:1070–1073. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas M, Pim D and Banks L: The role of
the E6-p53 interaction in the molecular pathogenesis of HPV.
Oncogene. 18:7690–7700. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Justus CR, Leffler N, Ruiz-Echevarria M
and Yang LV: In vitro cell migration and invasion assays. J Vis
Exp. 88:510462014.
|
|
29
|
Tian R, Zuo X, Jaoude J, Mao F, Colby J
and Shureiqi I: ALOX15 as a suppressor of inflammation and cancer:
Lost in the link. Prostaglandins Other Lipid Mediat. 132:77–83.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding XZ, Tong WG and Adrian TE:
Cyclooxygenases and lipoxygenases as potential targets for
treatment of pancreatic cancer. Pancreatology. 1:291–299. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bossler F, Hoppe-Seyler K and Hoppe-Seyler
F: PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk
in HPV-Positive Cervical Cancer Cells. Int J Mol Sci. 20:202019.
View Article : Google Scholar
|
|
32
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16 (Suppl
2):S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Milde-Langosch K: The Fos family of
transcription factors and their role in tumourigenesis. Eur J
Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brenner AK, Reikvam H, Lavecchia A and
Bruserud Ø: Therapeutic targeting the cell division cycle 25
(CDC25) phosphatases in human acute myeloid leukemia - the
possibility to target several kinases through inhibition of the
various CDC25 isoforms. Molecules. 19:18414–18447. 2014. View Article : Google Scholar : PubMed/NCBI
|
